U.S. Telecom Services and Carriers Stock News

Cummins (CMI) just locked in a $500 million contract with the U.S. Army for mobile power generators, a deal that reinforces its core power systems franchise and gives investors a fresh earnings catalyst. See our latest analysis for Cummins. The Army deal lands after a run of upbeat developments, including recent analyst upgrades, and helps extend what has already been a powerful move, with Cummins delivering a roughly mid-20s three-month share price return and a strong triple-digit three-year...

Archer-Daniels-Midland (ADM) just cut its full year outlook, pointing directly to choppy China trade and shifting biofuel policies. That combination has investors rethinking how durable recent earnings strength really is. See our latest analysis for Archer-Daniels-Midland. Even with today’s guidance cut weighing on sentiment, Archer-Daniels-Midland’s roughly 19 percent year to date share price return shows momentum has quietly improved, although the three year total shareholder return still...

Manchester United (MANU) shares have been grinding lower this year, down about 9% year to date and roughly 11% over the past year, leaving investors reassessing how much off pitch performance really matters. See our latest analysis for Manchester United. The recent drift lower, including a 1 day share price return of minus 2.41 percent and a 3 year total shareholder return of minus 29.52 percent, suggests momentum is still fading as investors reassess both growth prospects and ownership...

Mineralys Therapeutics recently announced that its Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or treatment-resistant hypertension was selected for JAMA’s inaugural “Research of the Year Roundup,” highlighting it as one of the most impactful studies published between October 2024 and September 2025. This recognition not only spotlights lorundrostat’s growing clinical profile but also underscores aldosterone’s emerging role as a key therapeutic target in difficult-to-treat...

Grab Holdings Ltd. recently refreshed its board, appointing former Madison Square Garden Entertainment and Bumble legal chief Laura Franco as an independent director while reassigning committee roles and accepting the retirement of long-serving director Ng Shin Ein. At the same time, new single-stock leveraged ETFs tied to Grab and upbeat analyst commentary on its fintech arm have drawn fresh attention to how governance, financial services expansion, and investor sentiment may shape the...

Comfort Systems USA recently presented at the Sidoti Year End Virtual Investor Conference and has been selected to join the S&P 500 index on December 22, 2025, replacing LKQ, Solstice Advanced Materials, and Mohawk Industries. This combination of index inclusion and a company message centered on backlog strength, margin expansion, and technology-focused projects is reshaping how investors view its long-term positioning. Next, we will examine how Comfort Systems USA’s upcoming addition to the...

If you have been wondering whether Bel Fuse is still good value after its huge run, you are not alone. This is one of those stocks where the price chart raises as many questions as it answers. Bel Fuse has climbed 4.1% over the last week, 15.0% over the past month, and an eye catching 70.4% year to date, with a staggering 333.4% gain over 3 years and 967.0% over 5 years reshaping how the market views its potential. Part of this momentum reflects growing attention on niche hardware and power...

RH (RH) has just posted its Q3 2026 numbers, with revenue at $883.8 million and basic EPS of $1.93, giving investors another data point in its ongoing earnings recovery story. The company has seen revenue move from $811.7 million in Q3 2025 to $883.8 million in Q3 2026, while basic EPS has shifted from $1.79 to $1.93 over the same period, alongside a trailing net margin that has stepped up from 2.2% to 3.2%. Taken together, the latest quarter points to a business that is squeezing more profit...

Hecla Mining (HL) has jumped onto traders’ screens after two catalysts hit at once: upcoming inclusion in the S&P MidCap 400 Index and a new high grade gold discovery at its Nevada Midas property. See our latest analysis for Hecla Mining. Those twin catalysts land on top of an already powerful run, with Hecla’s share price up 21.12 percent over 30 days and posting a standout 257.60 percent year to date share price return. Longer term total shareholder returns above 200 percent suggest...

Wondering if PPL at around $33.99 is quietly becoming a value opportunity, or if the easy money has already been made? You are not alone, as many investors are asking the same question. Over the last week the stock has inched up 0.4%, but that comes after a 7.8% slide over 30 days that still leaves it up 5.6% year to date and 8.7% over the past year, with longer term gains of 29.4% over 3 years and 52.9% over 5 years. These swings have come as investors reassess regulated utilities like PPL...

If you have ever wondered whether Roku is still a bargain or if most of the upside is already priced in, this breakdown is for you. After a bumpy few years, Roku shares are up 7.4% over the last week, 7.5% over the last month, 44.3% year to date, and 29.5% over the last year, even though the 5-year return is still down 68.5% from earlier peaks. Recently, investors have been digesting a mix of headlines around Roku's advertising momentum and its expanding content and distribution...

Why Home Depot Stock Is Back on Watch Home Depot (HD) has slipped about 11% over the past year and roughly 15% in the past 3 months, putting the stock back on many investors watchlists as housing and renovation trends evolve. See our latest analysis for Home Depot. Despite a steady 3 year total shareholder return of just over 20%, sentiment has cooled lately, with a roughly 15% 3 month share price pullback to about $359, as investors reassess housing demand and big ticket renovation spend. If...

If you are wondering whether Merck at around $100 a share is still a smart buy, or if most of the upside has already been priced in, you are in the right place. Merck’s share price has nudged up about 0.6% over the last week and 9.7% in the past month, but that still only translates to roughly 1.1% year to date and 2.0% over the last year, after a stronger 53.7% run over five years. Recent headlines have centered on Merck’s expanding oncology and vaccine franchises, with regulators...

If you are wondering whether Warner Bros. Discovery is still a value play after its big run up, or if you might be late to the party, this breakdown will help you decide whether the current price really makes sense. The stock has surged recently, climbing about 15.0% over the last week, 35.4% over the past month, and an eye catching 181.2% year to date. A 148.4% gain over the last year and 202.5% over three years has reshaped how the market views its potential. These moves have been driven...

If you are wondering whether Caterpillar's stock still offers value after such a big run, you are not alone, and this breakdown aims to cut through the noise. Despite slipping 0.9% over the last week, the stock is still up 4.3% over the past month, 66.2% year to date, and an impressive 263.4% over five years. This naturally raises questions about how much upside is left versus how much risk has been priced out. Recently, investors have been reacting to a mix of macro themes, from ongoing US...

Wondering if Synopsys at around $452 a share is still a smart buy or if the easy money has already been made? Let us unpack what the current market price may be missing about its long term value. The stock has slipped about 3% over the last week, but that comes after a strong 15% run in the past month, leaving shares still down 6.2% year to date and 10.9% over the last year while longer term holders sit on gains of 37.6% over 3 years and 77.6% over 5 years. Recent headlines around Synopsys...

Salesforce (CRM) just delivered an upside Q3, raised its fiscal 2026 revenue outlook, and backed that up with big Agentforce wins at the U.S. Department of Transportation and DeVry University, which is why the stock has investors leaning in. See our latest analysis for Salesforce. Even with the latest Agentforce wins and upgraded guidance, Salesforce’s 30 day share price return of 6.6% sits against a much weaker year to date share price performance. However, the three year total shareholder...

Sunoco has agreed a multi-year deal to return as a full-time primary partner in the NTT INDYCAR SERIES with Chip Ganassi Racing’s No. 8 Honda, driven by Kyffin Simpson, beginning in 2026, marking its first full-season primary partnership in the series since 1973. This renewed presence in top-tier open-wheel racing, alongside one of INDYCAR’s most successful teams, underscores Sunoco’s push to amplify its motorsports brand and highlight its high-performance fuel capabilities across more than...

In December 2025, The Buckle, Inc. announced that its board approved a US$3.00 per share special cash dividend alongside a US$0.35 regular quarterly dividend, both payable on January 29, 2026 to shareholders of record as of January 15, 2026. This combination of a sizable one-time payout and continued regular dividends highlights Buckle’s willingness to return excess cash to shareholders while maintaining its ongoing income stream. We’ll now look at how this large special dividend, alongside...

Insmed was recently added to the Nasdaq-100 Index and has seen continued accumulation by prominent institutional investor Stanley Druckenmiller, while Director Sharoky Melvin MD sold 20,000 shares for US$4,100,000 on 5 December 2025. This combination of index inclusion and visible institutional positioning has brought fresh attention to Insmed’s growing pulmonary-focused biopharma franchise and revenue profile. We’ll now examine how Insmed’s addition to the Nasdaq-100 could influence its...

Imperial Petroleum (IMPP) has just posted Q3 2025 results, with revenue of about $41.4 million and basic EPS of $0.33, keeping both the top and bottom line firmly in focus for investors tracking the story. The company has seen revenue move from roughly $33.0 million in Q3 2024 to $41.4 million this quarter, while basic EPS shifted from $0.29 to $0.33 over the same period, giving a clear sense of how the income statement has evolved year on year. With a trailing twelve month net profit margin...

Wondering if Atlanticus Holdings at around $65.96 is still a smart buy, or if the big gains are already behind it? This breakdown will help you decide whether the current price makes sense or is quietly offering value. The stock has jumped 10.6% over the last week and 25.8% in the past month, adding to a hefty 184.9% gain over 3 years and 151.5% over 5 years, which naturally raises questions about how much upside is left versus the risk of a pullback. Recent attention around Atlanticus has...

Vertex Pharmaceuticals recently reported clinical data showing that all evaluated children aged 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia treated with CASGEVY met key efficacy endpoints, and the FDA granted a Priority Review Voucher to accelerate review of the therapy in this younger age group. This progress in extending CASGEVY’s use to pediatric patients could meaningfully broaden its addressable patient population and support longer-term utilization of...

If you are wondering whether AST SpaceMobile is still a smart bet after its massive run, or if the real upside has already passed, this breakdown will walk through whether the current price really matches the story. The stock has risen 3.8% over the last week, 18.9% over the past month, and an eye-catching 254.4% year to date, with a 1887.0% gain over three years. These moves have been fueled by headline-grabbing milestones in its space-based mobile broadband ambitions and progress on key...